Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$59.97

52W Range

$31.52 - $68.58

50D Avg

$52.52

200D Avg

$45.57

Market Cap

$3.65B

Avg Vol (3M)

$490.89K

Beta

2.09

Div Yield

-

RYTM Company Profile


Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

226

IPO Date

Oct 09, 2017

Website

RYTM Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
License--
Product$77.43M-
License revenue-$6.75M
Product revenue-$16.88M

Fiscal year ends in Dec 23 | Currency in USD

RYTM Financial Summary


Dec 23Dec 22Dec 21
Revenue$77.43M$23.64M$3.15M
Operating Income$-184.36M$-179.16M$-170.06M
Net Income$-184.68M$-183.08M$-68.01M
EBITDA$-184.36M$-175.92M$-170.06M
Basic EPS-$-3.51$-1.37
Diluted EPS-$-3.51$-1.37

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 05, 24 | 10:45 PM
Q2 24Aug 06, 24 | 11:22 AM
Q1 24May 07, 24 | 12:00 AM

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
NUVLNuvalent, Inc.
AKROAkero Therapeutics, Inc.
ARVNArvinas, Inc.
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc. Warrant
KNSAKiniksa Pharmaceuticals, Ltd.
VRDNViridian Therapeutics, Inc.
MGTXMeiraGTx Holdings plc
RCKTRocket Pharmaceuticals, Inc.
VTYXVentyx Biosciences, Inc.
STOKStoke Therapeutics, Inc.
RNAAvidity Biosciences, Inc.
BDTXBlack Diamond Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
SNDXSyndax Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
ACLXArcellx, Inc.
SLDBSolid Biosciences Inc.
PTGXProtagonist Therapeutics, Inc.
QUREuniQure N.V.